This finding supported the in vivo study suggesting that recombinant (r)IL-3 administration into the cortices of AD mice model improved memory function [12] and the idea that astrocytic protein IL-3 could serve as a novel therapeutic approach for AD. This evidence concerns the gene IL3 and Alzheimer disease.